OUTCOMES:
THE
JUVÉDERM®
JOURNEY

Redefine what's possible in your patients' aesthetic treatment journey

With 10 FDA approvals, you can customize your patients' treatment journeys with the JUVÉDERM® Collection of Fillers.1-6

Actual patient. Results may vary. 

JUVÉDERM® IN FULL VIEW

Smooth. Natural-looking. Long-lasting1-13

JUVÉDERM® VOLUMA XC

VOLUMIZE CHEEKS FOR LIFT

Longest-lasting HA filler for the cheeks—results last up to 2 years1,14-17,*

SHAPE THE CHIN

Long-lasting—results last up to 1 year1,*

VOLUMIZE THE TEMPLES FOR LIFT

Long-lasting—results last beyond 1 year1,*

JUVÉDERM® VOLUX XC

REDEFINE THE JAWLINE

Long-lasting—results last up to 1 year2,*

*With optimal treatment.

LONGEST-LASTING HA filler collection for the lips, with results up to 1 year3,4,18-22,*

JUVÉDERM® ULTRA XC

PLUMP THE LIPS

Long-lasting—results last up to 1 year3,*

JUVÉDERM® VOLBELLA® XC

ENHANCE LIPS & SOFTEN LIP LINES

Long-lasting—results last up to 1 year4,*

*With optimal treatment.

JUVÉDERM® VOLLURE® XC

SMOOTH SMILE LINES

Longest-lasting HA filler for facial wrinkles and folds—results last up to 18 months 3-6,14,20,22-28,*

JUVÉDERM® ULTRA PLUS XC

FILL SMILE LINES

Long-lasting—results last beyond 1 year6,*

*With optimal treatment.

JUVÉDERM® VOLBELLA® XC

IMPROVE THE UNDEREYE HOLLOWS

Long-lasting—results last up to 1 year4,*

*With optimal treatment.

KRISTIN’S JUVÉDERM® JOURNEY

BOLD &
BALANCED

“I came in looking for natural-looking results, and that's exactly what I got with JUVÉDERM®!”

AGE

40s

PROFESSION

Registered Dietitian 

TREATMENT DETAILS

3 different JUVÉDERM® products, 5 areas treated in total

Actual patient treated with JUVÉDERM® VOLUMA® XC in the midface, chin, and temples, JUVÉDERM® VOLLURE® XC in the nasolabial folds and marionette lines, and JUVÉDERM® VOLBELLA® XC in the infraorbital hollows. Results may vary.

CHERUB’S JUVÉDERM® JOURNEY

SAVVY &
SENSATIONAL

“I got the look that I wanted—natural and subtle.”

AGE

40s

PROFESSION

Screenwriter

TREATMENT DETAILS

3 products across 3 areas

Actual patient treated with JUVÉDERM® VOLUMA® XC in the midface, JUVÉDERM® VOLLURE® XC in the nasolabial folds and marionette lines, and JUVÉDERM® VOLBELLA® XC in the infraorbital hollows and lips. Results may vary.

CHERYL’S JUVÉDERM® JOURNEY

DAZZLING &
DEFINED

“The added volume in my cheeks and subtle fullness of my lips are just what I hoped for! I can't wait to show off my new look!”

AGE

60s

PROFESSION

Professor

TREATMENT DETAILS

4 different JUVÉDERM® products, 5 areas treated in total

Actual patient treated with JUVÉDERM® VOLUMA® XC in the midface, JUVÉDERM® VOLLURE® XC in the nasolabial folds and marionette lines, JUVÉDERM® VOLBELLA® XC in the infraorbital hollows and lips, and JUVÉDERM® VOLUX® XC in the jawline. Results may vary.

JAZZ’S JUVÉDERM® JOURNEY

POLISHED &
PLAYFUL

“My lips, cheeks, and jawline are exactly the way I wanted—with a natural look.”

AGE

20s

PROFESSION

Public Relations 

TREATMENT DETAILS

3 different JUVÉDERM® products, 3 areas treated in total

Actual patient treated with JUVÉDERM® VOLUMA® XC in the midface, JUVÉDERM®
Ultra XC in the lips, and JUVÉDERM® VOLUX® XC in the jawline. Results may vary

KATE’S JUVÉDERM® JOURNEY

PRECISE &
POISED

“Smooth, less tired-looking* undereyes is exactly what I was going for—nothing is overdone.”

AGE

40s

PROFESSION

Sociologist

TREATMENT DETAILS

4 different JUVÉDERM® products, 5 areas treated in total

Actual patient treated with JUVÉDERM® VOLUMA® XC in the midface and chin, JUVÉDERM® VOLBELLA® XC in the infraorbital hollows, JUVÉDERM® VOLLURE® XC in the nasolabial folds and marionette lines, and JUVÉDERM® Ultra XC in the lips. Results may vary.

STERLING’S JUVÉDERM® JOURNEY

SMOOTH &
STRUCTURED

“I am so happy with the subtle results in my undereye area and jawline—and that they’re long-lasting!”

AGE

30s

PROFESSION

Software Engineer

TREATMENT DETAILS

3 different JUVÉDERM® products, 3 areas treated in total

Actual patient treated with JUVÉDERM® VOLUMA® XC in the midface, JUVÉDERM® VOLBELLA® XC in the infraorbital hollows, and JUVÉDERM® VOLUX® XC in the jawline. Results may vary.

References: 1.  JUVÉDERM® VOLUMA® XC Directions for Use, June 2024. 2. JUVÉDERM® VOLUX™ XC Directions for Use, May 2023. 3. JUVÉDERM® Ultra XC Directions for Use, May 2023. 4. JUVÉDERM® VOLBELLA® XC Directions for Use, May 2023. 5. JUVÉDERM®  VOLLURE™ XC Directions for Use, May 2023. 6. JUVÉDERM® Ultra Plus XC Directions for Use, May 2023. 7. Data on file, Allergan, October 11, 2018; CSR JUVÉDERM® VOLUMA™ XC-006. 8. Data on file, Allergan, August 31, 2012; Interim 24-Month Study Report: JUVÉDERM® VOLUMA™ XC-002. 9. Geronemus RG, Bank DE, Hardas B, Shamban A, Weichman BM, Murphy DK. Safety and effectiveness of VYC-15L, a hyaluronic acid filler for lip and perioral enhancement: one-year results from a randomized, controlled study. Dermatol Surg. 2017;43:396-404. 10. Fabi S, Zoumalan C, Fagien S, et al. Effectiveness of Volbella (VYC-15L) for infraorbital hollowing: patient-reported outcomes from a prospective, multicenter, single-blind, randomized, controlled study. Aesthet Surg J. 2023;43(11):1357-1366. 11. Monheit G, Beer K, Hardas B, et al. Safety and effectiveness of the hyaluronic acid dermal filler VYC-17.5L for nasolabial folds: results of a randomized, controlled study. Dermatol Surg. 2018;44:670-678. 12. Pinsky MA, Thomas JA, Murphy DK, Walker PS; for JUVÉDERM® vs ZYPLAST®  Nasolabial Fold Study Group. JUVÉDERM® injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthetic Surg J. 2008;28(1):17-23. 13. Data on file, Allergan, January 26, 2021; Clinical Study Report V25L-002. 14. Restylane Lyft Instructions for Use, August 2023. 15. Restylane Contour Instructions for Use, October 2024. 16. RHA Redensity Instructions for Use, August 2023.17. Restylane Eyelight Instructions for Use, January 2023. 18. Restylane Kysse Instructions for Use, September 2023. 19. Restylane Silk Instructions for Use, June 2023. 20. RHA 3 Instructions for Use, October 2023. 21. Revanesse Lips+ Instructions for Use, 2020. 22. Restylane-L Instructions for Use, September 2023. 23. Restylane Refyne Instructions for Use, September 2023. 24. Restylane Defyne Instructions for Use, August 2023. 25. Belotero Balance Instructions for Use, September 2023. 26. Revanesse Versa+ Instructions for Use, 2020. 27. RHA 2 Instructions for Use, January 2021. 28. RHA 4 Instructions for Use, January 2021.

IMPORTANT SAFETY INFORMATION & APPROVED USES

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

APPROVED USES JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss, for augmentation of the chin region to improve the chin profile, and for augmentation of the temple region to improve moderate to severe temple hollowing in adults over 21...

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

INDICATIONS

JUVÉDERM® VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face, for augmentation of the chin region to improve the chin profile, and for supraperiosteal injection to augment the temple region to improve moderate to severe temple hollowing in adults over the age of 21.

JUVÉDERM® VOLUX® XC injectable gel is indicated for subcutaneous and/or supraperiosteal injection for improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.

JUVÉDERM® VOLLURE® XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

JUVÉDERM® VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.

JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

JUVÉDERM® Ultra XC injectable gel is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

JUVÉDERM® Collection of Fillers Indications and Important Safety Information

CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products

WARNINGS

  • Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
  • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

ADVERSE EVENTS

The most common reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. The majority were mild or moderate in severity.

To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan® Product Support at 1-877-345-5372. Please visit rxabbvie.com for more information.

Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

PRECAUTIONS

  • To minimize the risk of potential complications, these products should only be used by healthcare professionals who are knowledgeable about the anatomy and the product(s) for use in indicated area(s), and who have appropriate training in facial anatomy, vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications
  • The potential risks of soft tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
  • The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each product have not been established in controlled clinical studies
  • The safety for use of these products in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
  • The safety for use during pregnancy and in breastfeeding females has not been established
  • The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age for cheek augmentation, 22 and 80 years of age for chin augmentation, and 32 and 82 years of age for improvement of temple hollowing
  • The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and the safety for use of JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC, and JUVÉDERM® VOLBELLA® XC in patients under 22 years, has not been established
  • Dermal filler implantation carries a risk of infection. Follow standard precautions
  • Dermal fillers should be used with caution in patients on immunosuppressive therapy
  • Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
  • Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
  • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site
  • The safety for use of JUVÉDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established
  • The safety of using a cannula with JUVÉDERM® VOLUMA® XC for cheek augmentation in patients with Fitzpatrick Skin Types V and VI or to improve temple hollowing has not been established
  • JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
  • The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
  • Patients may experience late-onset adverse events with injectable gel implants, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC
  • Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lb) body mass per year. The safety of injecting greater amounts has not been established
  • Injection of more than 9 mL of JUVÉDERM® VOLUX® XC for improvement of jawline definition has not been studied